Company / Gross Margin
Organon & Co. Gross Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
53.3%
FY2025
5-year range
53.3% / 62.8%
FY2022-FY2025
Trend
-8.1%
vs FY2024
Sector context
#18 of 28
Health Care
What the data says
At 53.3%, Organon & Co.'s gross margin ranks #18 of 28 in the Health Care sector. Gross Margin has declined for 3 consecutive years, from 62.8% in FY2022 to 53.3% in FY2025.
Based on SEC 10-K filings.
53.3% in FY2025 with a 3-year CAGR of -9.5%.
Declined from 59.8% to 53.3% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -9.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#18 of 28 in Health CareTop 64% of 28This company 53.3% Sector average 60.3%
▼
-11.6% below sector average
Key checks
Key Insights
- Organon & Co.'s gross margin has declined for 3 consecutive years.
- In FY2025, gross margin decreased 8.1% year-over-year.
- Currently 7.0pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 53.3% | -8.1% |
| FY2024 | 58.0% | -3.0% |
| FY2023 | 59.8% | -4.8% |
| FY2022 | 62.8% | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026